Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 111, Issue 6, 2004, Pages 613-618

  Santin, Alessandro D ^a,e   Ravindranath, Mepur H ^b   Bellone, Stefania ^a   Muthugounder, Sakunthala ^b   Palmieri, Michela ^a   O'Brien, Timothy J ^a   Roman, Juan ^a   Cannon, Martin J ^c   Pecorelli, Sergio ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE;

ADULT; AGED; ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEAL FLUID; PRIORITY JOURNAL; PROSPECTIVE STUDY; UTERINE CERVIX CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CELL LINE, TUMOR; FEMALE; GANGLIOSIDES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES;

EID: 2942548853     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00142.x     Document Type: Article

References (38)

1. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
2. Berek JS, Bast RC, Lichtenstein A, et al. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol 1984;64:708-714.
3. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman CM. Tumor-host interaction: analysis of cytokines, growth factors, and tumor infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997;28:321-331.
4. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-5318.
5. Kong Y, Li R, Ladisch S. Natural forms of shed tumor gangliosides. Biochim Biophys Acta 1998;1394:43-56.
6. Saqr HE, Pearl DK, Yates AJ. A review and predictive models of ganglioside uptake by biological membranes. J Neurochem 1993;61: 395-411.
7. Ladisch S, Li R, Olson E. Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc Natl Acad Sci USA 1994;91: 1974-1978.
8. Irani DN, Lin KI, Griffin DE. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 1996;157:4333-4340.
9. Ladisch S, Wu ZL. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1985;1:136-138.
10. Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 1983;43:3808-3813.
11. Bernhard H, Meyer zum Buschenfelde KH, Dippold WG. Ganglioside GD3 shedding by human malignant melanoma cells. Int J Cancer 1989;44:155-160.
12. Merritt WD, Der-Minassian V, Reaman GH. Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia. Leukemia 1994;8:816-822.
13. Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990;75:1564-1567.
14. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999;73: 5402-5410.
15. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid eluted peptide pulsed autologous dendritic cells. Obstet Gynecol 2000;96:422-430.
16. Santin AD, Bellone S, Ravaggi A, et al. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer 2002;86:151-157.
17. Chu KU, Ravindranath MH, Gonzales A, et al. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 2000; 88:1828-1836.
18. Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J 2002;8:384-394.
19. Svennerholm L. Quantitative estimation of sialic acid. II: A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 1957;24:604-611.
20. Schengrund C-L, Repman MA. Density-dependent changes in gangliosides in gangliosides and sialidase activity of murine neuroblastoma cells. J Neurochem 1982;39:940-947.
21. Portoukalian J, David MJ, Shen X, Richard M, Dubreuil C. Tumor size-dependent elevations of serum gangliosides in patients with head and neck carcinomas. Biochem Int 1989;18:759-765.
22. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale Jr EM. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001;61:363-369.
23. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003;170:3488-3494.
24. Gong J, Nikrui N, Chen D, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000;165:1705-1711.
25. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
26. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
27. Thurner B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-1678.
28. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cells hybrid. Nat Med 2000;6:332-336.
29. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-8519.
30. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. HPV-18 E7 pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002;346:1752-1753.
31. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193: 233-238.
32. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002;100:174-177.
33. Melichar B, Savary C, Kudelka AP, et al. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998;4:799-809.
34. Ziegler-Heitbrock HW, Kafferlein E, Haas JG, et al. Gangliosides suppress tumor necrosis factor production in human monocytes. J Immunol 1992;148:1753-1758.
35. Cavaillon JM, Fitting C. Inhibition of lipopolysaccharide-induced monocyte interleukin 1 secretion by gangliosides. Eur J Immunol 1986;16:1009-1012.
36. Kanda N. Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun 1999;256: 41-44.
37. Santin AD, Hermonat PL, Ravaggi A, et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 2001;51:254-261.
38. Li R, Ladisch S. Abrogation of shedding of immunosuppressive neuroblastoma gangliosides. Cancer Res 1996;56:4602-4605.